Immunomedics, Inc., (Nasdaq: IMMU) announced that the Company is terminating the Phase 3 PANCRIT-1 trial with yttrium-90-labeled (90Y) clivatuzumab tetraxetan ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments Trader Talk

Jefferies Cuts Price Target on Immunomedics (IMMU) as Clivatuzumab Program is Discontinued March 15, 2016 8:15 AM Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic CancerMarch 14, 2016 4:30 PM